ADRB2 p.Thr164Ile association with hospitalization depends upon asthma severity - 04/05/19
Doi : 10.1016/j.jaci.2019.01.012
Lynn D. Condreay, PhD a, b 
, Mathias N. Chiano, PhD c, Li Li, PhD b, Elizabeth Harris, BSc a, b, Dana J. Fraser, MSc b, Deborah A. Meyers, PhD d, Eugene R. Bleecker, MD d, Courtney Crim, MD a, David Stempel, MD a, e, Steven W. Yancey, MSc a, Soumitra Ghosh, MD, PhD f
, Mathias N. Chiano, PhD c, Li Li, PhD b, Elizabeth Harris, BSc a, b, Dana J. Fraser, MSc b, Deborah A. Meyers, PhD d, Eugene R. Bleecker, MD d, Courtney Crim, MD a, David Stempel, MD a, e, Steven W. Yancey, MSc a, Soumitra Ghosh, MD, PhD f a GlaxoSmithKline, Research Triangle Park, NC
b PAREXEL International, Durham, NC
c GlaxoSmithKline, Stevenage, United Kingdom
d University of Arizona College of Medicine, Tucson, Ariz
e Propeller Health, Madison, Wis
f GlaxoSmithKline, King of Prussia, Pa
| This pharmacogenetic study was funded by GlaxoSmithKline (United Kingdom) (study nos. 204661, 205064, and 205643). Genetic samples and data were from GlaxoSmithKline studies ADA109055, ADA109057, and HZA106837 (in study 204661), MEA201722 (in study 205064), and MEA122997 and MEA115588 (in study 205643). This study was conceived and implemented by the coauthors and sponsored and funded by GlaxoSmithKline. The protocol, available as part of the online data supplement, was developed in collaboration between the employees of the sponsor and the principal academic investigators. |
|
| Disclosure of potential conflict of interest: L. D. Condreay and D. J. Fraser are former GlaxoSmithKline employees and hold shares; they are currently PAREXEL International employees working under a GlaxoSmithKline contract. M. N. Chiano, C. Crim, and S. W. Yancey are GlaxoSmithKline employees and hold shares. L. Li, E. Harris, and D. Stempel are former GlaxoSmithKline employees and hold shares. E. R. Bleecker has undertaken clinical trials through his employer, Wake Forest School of Medicine and University 33 of Arizona, for AstraZeneca, MedImmune, Boehringer Ingelheim, Cephalon/Teva, Genentech, Johnson and Johnson (Janssen), Novartis, Regeneron, and Sanofi Genzyme; is also a paid consultant for AztraZeneca, MedImmune, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Regeneron, and Sanofi Genzyme. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2019
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 143 - N° 5
P. 1962 - mai 2019 Retour au numéro
Article précédent
- Beta-defensins are proinflammatory pruritogens that activate Mrgprs
- Li Zhang, Benjamin D. McNeil
- Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept
- Carrie Brodmerkel, Katherine Li, Sandra Garcet, Karen Hayden, Andrea Chiricozzi, Inna Novitskaya, Judilyn Fuentes-Duculan, Mayte Suarez-Farinas, Kim Campbell, James G. Krueger
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?